The growing number of FDA-approved and experimental drugs targeting PD-1, PD-L1, and PD-L2 suggests that immuno-senolytic strategies promoting tumor regression via CD8+ T cells and cancer therapies inducing senescence will be developed in the near future. This evidence concerns the gene PDCD1LG2 and cancer.